Status:
COMPLETED
Long-term Impact of NMDAR Encephalitis
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Autoimmune Encephalitis
Eligibility:
All Genders
18-80 years
Brief Summary
NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR enc...
Detailed Description
This study will help improve the management of patients with anti-NMDAR encephalitis : * By providing the first assessment of long-term cognitive, psychological and social consequences * By character...
Eligibility Criteria
Inclusion
- Patients with NMDAR encephalitis
- Age ≥ 18 years old
- Patient affiliated to a social security system
- No opposition from the patient
Exclusion
- Patients whithout NMDAR encephalitis
- Age \< 18 years old
- Patient under guardianship or curatorship
- Patient with neurological disorders pre-existing encephalitis
Key Trial Info
Start Date :
December 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 4 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06609044
Start Date
December 16 2024
End Date
April 4 2025
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER
Bron, France, 69500